|
MURAGAKI Yoshihiro
Department School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine Position Visiting Professor |
|
| Article types | Original article |
| Language | English |
| Peer review | Peer reviewed |
| Title | Global post-marketing safety surveillance of Tumor Treating Fields (TTFields) in patients with high-grade glioma in clinical practice. |
| Journal | Formal name：Journal of neuro-oncology Abbreviation：J Neurooncol ISSN code：15737373/0167594X |
| Domestic / Foregin | Foregin |
| Volume, Issue, Page | 148(30),pp.489-500 |
| Author and coauthor | SHI Shi Wenyin†*, BLUMENTHAL Deborah T, OBERHEIM-BUSH Nancy Ann, KEBIR Sied, LUKAS Rimas V, MURAGAKI Yoshihiro, ZHU Jay-Jiguang, GLAS Martin |
| Publication date | 2020/07 |
| Summary | INTRODUCTION:Tumor Treating Fields (TTFields; antimitotic treatment) delivers low-intensity, intermediate-frequency, alternating electric fields through skin-applied transducer arrays. TTFields (200 kHz) was FDA-approved in glioblastoma (GBM), based on the phase 3 EF-11 (recurrent GBM, rGBM) and EF-14 (newly diagnosed GBM, ndGBM) trials. The most common TTFields-related adverse event (AE) in both trials was array-associated skin irritation. We now report on TTFields-related AEs in the real-world, clinical practice setting |
| DOI | 10.1007/s11060-020-03540-6 |
| PMID | 32535723 |